Aisling S Last1, Patrik Pipkorn1, Stephanie Chen1, Dorina Kallogjeri1, Joseph Zenga2, Jason T Rich1, Randal Paniello1, Jose Zevallos1, Rebecca Chernock3, Douglas Adkins4, Peter Oppelt4, Hiram Gay5, Mackenzie Daly5, Wade Thorstad5, Ryan S Jackson1. 1. Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri. 2. Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee. 3. Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri. 4. Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri. 5. Department of Radiation Oncology, Washington University School of Medicine in St Louis, St Louis, Missouri.
Abstract
Importance: The optimal treatment strategy for patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) of the base of the tongue (BOT) has not been sufficiently studied. Objective: To investigate the rate of and risk factors for occult contralateral nodal disease in patients with HPV-related BOT OPSCC undergoing transoral surgery and bilateral neck dissections. Design, Setting, and Participants: This retrospective case series reviewed the medical records of patients with HPV-related BOT OPSCC who underwent transoral surgery and bilateral neck dissections from January 1, 2002, through December 31, 2018, at the tertiary care center of Washington University School of Medicine in St Louis. Patients had a median follow-up of 30.0 months (interquartile range, 11.0-60.4 months). Patients with recurrent disease or multiple synchronous OPSCC primary tumors were excluded for a total of 89 patients. Data were analyzed from January 1 through June 1, 2019. Main Outcomes and Measures: The primary outcome was the rate of contralateral occult nodal disease. Secondary outcomes were potential risk factors for contralateral occult nodal disease and regional recurrence rates. Results: Eighty-nine patients were included in the series, of whom 81 (91.0%) were men. The mean (SD) age was 60 (9) years. Overall, 34 patients (38.2%) had pathologic contralateral nodal metastases. Seventy patients had no clinical evidence of contralateral nodal disease. Of these 70, occult nodes were identified in 15 (21.4%). Risk of contralateral disease was higher when the primary tumor crossed midline (odds ratio, 6.23; 95% CI, 1.71-22.77). Of the 55 patients with no occult disease identified, only 2 (3.6%) received radiotherapy to the contralateral neck, and no regional recurrence of disease was noted. Conclusions and Relevance: Given the rate of occult contralateral nodal disease of 21.4%, it appears that contralateral elective neck dissection or radiotherapy should be recommended in patients with HPV-related BOT OPSCC. Patients with a pathologically negative result of contralateral neck dissection may not benefit from radiotherapy to that nodal basin. Future prospective investigations should evaluate functional and oncologic outcomes of contralateral elective neck dissection compared with elective radiotherapy in the contralateral neck for HPV-related BOT OPSCC.
Importance: The optimal treatment strategy for patients with human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) of the base of the tongue (BOT) has not been sufficiently studied. Objective: To investigate the rate of and risk factors for occult contralateral nodal disease in patients with HPV-related BOT OPSCC undergoing transoral surgery and bilateral neck dissections. Design, Setting, and Participants: This retrospective case series reviewed the medical records of patients with HPV-related BOT OPSCC who underwent transoral surgery and bilateral neck dissections from January 1, 2002, through December 31, 2018, at the tertiary care center of Washington University School of Medicine in St Louis. Patients had a median follow-up of 30.0 months (interquartile range, 11.0-60.4 months). Patients with recurrent disease or multiple synchronous OPSCC primary tumors were excluded for a total of 89 patients. Data were analyzed from January 1 through June 1, 2019. Main Outcomes and Measures: The primary outcome was the rate of contralateral occult nodal disease. Secondary outcomes were potential risk factors for contralateral occult nodal disease and regional recurrence rates. Results: Eighty-nine patients were included in the series, of whom 81 (91.0%) were men. The mean (SD) age was 60 (9) years. Overall, 34 patients (38.2%) had pathologic contralateral nodal metastases. Seventy patients had no clinical evidence of contralateral nodal disease. Of these 70, occult nodes were identified in 15 (21.4%). Risk of contralateral disease was higher when the primary tumor crossed midline (odds ratio, 6.23; 95% CI, 1.71-22.77). Of the 55 patients with no occult disease identified, only 2 (3.6%) received radiotherapy to the contralateral neck, and no regional recurrence of disease was noted. Conclusions and Relevance: Given the rate of occult contralateral nodal disease of 21.4%, it appears that contralateral elective neck dissection or radiotherapy should be recommended in patients with HPV-related BOT OPSCC. Patients with a pathologically negative result of contralateral neck dissection may not benefit from radiotherapy to that nodal basin. Future prospective investigations should evaluate functional and oncologic outcomes of contralateral elective neck dissection compared with elective radiotherapy in the contralateral neck for HPV-related BOT OPSCC.
Authors: Moustafa Mourad; Thomas Jetmore; Ameya A Jategaonkar; Sami Moubayed; Erin Moshier; Mark L Urken Journal: J Oral Maxillofac Surg Date: 2017-05-22 Impact factor: 1.895
Authors: Jessika A Contreras; Christopher Spencer; Todd DeWees; Bruce Haughey; Lauren E Henke; Re-I Chin; Randal Paniello; Jason Rich; Ryan Jackson; Peter Oppelt; Patrik Pipkorn; Jose Zevallos; Rebecca Chernock; Brian Nussenbaum; Mackenzie Daly; Hiram Gay; Douglas Adkins; Wade Thorstad Journal: J Clin Oncol Date: 2019-06-27 Impact factor: 44.544
Authors: Peter T Dziegielewski; Daniel A O'Connell; Jacek Szudek; Brittany Barber; Arjun Joshi; Jeffrey R Harris; Hadi Seikaly Journal: Head Neck Date: 2012-09-25 Impact factor: 3.147
Authors: Re-I Chin; Yuan James Rao; Michael Y Hwang; Christopher R Spencer; Michael Pierro; Todd DeWees; Pranav Patel; Parul Sinha; Hiram A Gay; Mackenzie Daly; Bruce H Haughey; Brian Nussenbaum; Douglas R Adkins; James S Lewis; Wade L Thorstad Journal: Cancer Date: 2017-09-07 Impact factor: 6.860
Authors: Nosayaba Osazuwa-Peters; Matthew C Simpson; Sean T Massa; Eric Adjei Boakye; Jastin L Antisdel; Mark A Varvares Journal: Oral Oncol Date: 2017-10-02 Impact factor: 5.337
Authors: Carlos Miguel Chiesa-Estomba; Juan David Urazan; Cammaroto Giovanni; Mannelli Giuditta; Molteni Gabriele; Dallari Virginia; R Lechien Jerome; Miguel Mayo-Yanez; José Ángel González-García; Jon Alexander Sistiaga-Suarez; Tucciarone Manuel; Ayad Tareck; Meccariello Giuseppe Journal: Eur Arch Otorhinolaryngol Date: 2022-09-14 Impact factor: 3.236
Authors: Mattis Bertlich; Nina Zeller; Saskia Freytag; Jennifer L Spiegel; Bernhard G Weiss; Martin Canis; Frank Haubner; Friedrich Ihler Journal: BMC Surg Date: 2022-05-19 Impact factor: 2.030
Authors: Mihir R Patel; Lauren Ottenstein; Martha Ryan; Annie Farrell; Matthew Studer; H Michael Baddour; Kelly Magliocca; Christopher Griffith; William Stokes; Jeffrey Switchenko; Ashley Aiken; Mark El-Deiry; C Arturo Solares; Conor Steuer; Nabil Saba; Jonathan Beitler Journal: Oral Oncol Date: 2021-04-17 Impact factor: 5.337